CU23419A1 - NMB0088 PROTEIN AND ITS USE IN PHARMACEUTICAL FORMULATIONS - Google Patents
NMB0088 PROTEIN AND ITS USE IN PHARMACEUTICAL FORMULATIONSInfo
- Publication number
- CU23419A1 CU23419A1 CU20030284A CU20030284A CU23419A1 CU 23419 A1 CU23419 A1 CU 23419A1 CU 20030284 A CU20030284 A CU 20030284A CU 20030284 A CU20030284 A CU 20030284A CU 23419 A1 CU23419 A1 CU 23419A1
- Authority
- CU
- Cuba
- Prior art keywords
- nmb0088
- protein
- formulations
- inducing
- antigen
- Prior art date
Links
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Uso de un nuevo antígeno vacunal aplicado de manera preventiva o terapéutica contra enfermedades bacterianas, virales, cancerosas, o de otro origen. El objetivo técnico que se persigue es el desarrollo de formulaciones capaces de elevar el espectro protector de las vacunas ya existentes y extenderlo contra diferentes patógenos. Para lograr este objetivo se aisló e identificó la proteína NMB0088 como componente de las preparaciones de membrana externa de Neisseria meningitidis, capaz de inducir actividad bactericida. Adicionalmente se clonó y expresó el gen codificante para la proteína NMB0088, la cual se puificó evaluándose luego su inmunogenicidad en biomedelos animales. El secuenciamiento de genes homólogos evidenció, por su elevado grado de conservación, su alto valor como antígeno inductor de una respuesta inmune cruzada cuando es presentado por diferentes vías. LAs formulaciones resultantes de esta invención son aplicables en la industria farmacéutica como formulaciones vacunales para uso humano.Use of a new vaccine antigen applied in a preventive or therapeutic way against bacterial, viral, cancerous or other diseases. The technical objective pursued is the development of formulations capable of raising the protective spectrum of existing vaccines and extending it against different pathogens. To achieve this objective, the NMB0088 protein was isolated and identified as a component of Neisseria meningitidis external membrane preparations, capable of inducing bactericidal activity. Additionally, the gene coding for the NMB0088 protein was cloned and expressed, which was then puffed and its immunogenicity was evaluated in animal biomedels. The sequencing of homologous genes evidenced, due to its high degree of conservation, its high value as an antigen inducing a cross-immune response when presented by different routes. The formulations resulting from this invention are applicable in the pharmaceutical industry as vaccine formulations for human use.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU20030284A CU23419A1 (en) | 2003-12-03 | 2003-12-03 | NMB0088 PROTEIN AND ITS USE IN PHARMACEUTICAL FORMULATIONS |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU20030284A CU23419A1 (en) | 2003-12-03 | 2003-12-03 | NMB0088 PROTEIN AND ITS USE IN PHARMACEUTICAL FORMULATIONS |
Publications (1)
Publication Number | Publication Date |
---|---|
CU23419A1 true CU23419A1 (en) | 2009-09-08 |
Family
ID=41203572
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CU20030284A CU23419A1 (en) | 2003-12-03 | 2003-12-03 | NMB0088 PROTEIN AND ITS USE IN PHARMACEUTICAL FORMULATIONS |
Country Status (1)
Country | Link |
---|---|
CU (1) | CU23419A1 (en) |
-
2003
- 2003-12-03 CU CU20030284A patent/CU23419A1/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1117757T1 (en) | MODIFIED RSV F PROTEINS AND METHODS OF USE | |
NO20044940L (en) | Recombinant poxvirus expressing homologous genes inserted into the poxviral genome | |
CY1119285T1 (en) | Adenosine Chimpanzee Vaccine Carriers | |
CY1108875T1 (en) | Mucilage-containing formulas containing xyloglycan and which are useful in medical devices and pharmaceutical formulations | |
CY1119198T1 (en) | STABLE COMPOSITION INCLUDING PTHrP AND USE OF THIS USE | |
CY1118555T1 (en) | GENDER TREATMENT FOR SUBJECTIVE LABORATORY SCIENCE AND OTHER SPINAL DISEASES | |
WO2007022425A3 (en) | Influenza recombinant subunit vaccine | |
NO20054608L (en) | Influenza vaccine | |
WO2007054283A3 (en) | Pqs and its conjugates as adjuvants and their uses in pharmaceutical compositions | |
CY1111916T1 (en) | VACCINATED VACCINATED ROTAIUS VACCINE FOR ADMINISTRATION OF THE ORAL | |
AR083561A1 (en) | PREPARATION OF AN ANTIGENIC CONSTRUCTION | |
MX2010012999A (en) | Meningococcal multivalent native outer membrane vesicle vaccine, methods of making and use thereof. | |
NO20071875L (en) | Bicyclic amides as kinase inhibitors | |
NO20063047L (en) | Aqueous ciclesonide suspensions for nebulization | |
TNSN07087A1 (en) | Stable liquid formulations of plasmid dna | |
BRPI0606614A2 (en) | peptides for mucosal vaccine delivery | |
AR046937A1 (en) | PROTEIN NMB0928 AND ITS USE IN PHARMACEUTICAL FORMULATIONS | |
DE60336588D1 (en) | IMPROVED ANTHRAXIMP AND METHOD OF DELIVERY | |
CU23419A1 (en) | NMB0088 PROTEIN AND ITS USE IN PHARMACEUTICAL FORMULATIONS | |
CU23435A1 (en) | NMB2134 PROTEIN AND ITS USE IN PHARMACEUTICAL FORMULATIONS | |
CU23237A1 (en) | PROTEIN NMB1125 AND ITS USE IN PHARMACEUTICAL FORMULATIONS | |
NO20045587L (en) | Liposome vaccine formulation for finding fish | |
BR112014007491A2 (en) | amino acid sequences for pathogen control | |
CU23572A1 (en) | PHARMACEUTICAL COMPOSITION INCLUDING PROTEIN NMB0938 | |
AR046921A1 (en) | METHOD FOR THE INCORPORATION OF ANTIGENS IN EXTERNAL MEMBRANE VESICULES OF BACTERIA AND RESULTING FORMULATIONS |